Who invested in Enliven Therapeutics

One round we have observed, with the 4 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Raised 5 months ago

Funding summaryUpdated 26 Oct 2026

$460Mraised across 1 round since 2026, from 1 source

Latest round: Round, $460MJun 2026
Investors: 4

See who backed them

The rounds

Jun 2026
Round$460M
Source recorded

Founders and team

From Enliven Therapeutics's own website and the SEC filings it signed: 7 on the team.

Ben HohlChief Financial Officer and Head of Corporate Development
Anish P. PatelExecutive Officeri
Benjamin P. HohlExecutive Officeri
Helen P. CollinsExecutive Officeri
Jake P. BauerBoard of Directors
Joseph P. LyssikatosExecutive Officer, Directori
Samuel KintzExecutive Officer, Directori

On the board, as filediAndrew P. PhillipsMika P. DerynckRahul P. BallalRichard P. HeymanRishi P. Gupta

Everyone who backed them

OrbiMedPrivate equity1round

Janus Henderson InvestorsPrivate equity1round

Cormorant Asset ManagementPrivate equity1round

5AM VenturesVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Enliven Therapeutics

Who invested in Enliven Therapeutics?

Enliven Therapeutics's investors include OrbiMed, Janus Henderson Investors, Cormorant Asset Management and 5AM Ventures.

How much has Enliven Therapeutics raised?

Enliven Therapeutics has raised $460M across 1 round since 2026.

When did Enliven Therapeutics last raise?

Enliven Therapeutics's most recent round was an Undisclosed round of $460M in Jun 2026.

What was Enliven Therapeutics's biggest round?

Its most recent round, $460M in Jun 2026, is also its largest on record.

Who backed Enliven Therapeutics first?

Enliven Therapeutics's first round on record, in Jun 2026, was backed by OrbiMed, Janus Henderson Investors and Cormorant Asset Management and 1 others.